Related Experiment Videos
PARP inhibitors for cancer therapy
1University of Newcastle upon Tyne, Northern Institute for Cancer Research, Paul O'Gorman Building, Medical School, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK. n.j.curtin@ncl.ac.uk
Expert Reviews in Molecular Medicine
|April 20, 2005
Summary
Poly(ADP-ribose) polymerase 1 (PARP-1) inhibitors enhance cancer therapy by increasing sensitivity to DNA-damaging agents. Combining PARP inhibitors with temozolomide shows promise, leading to complete tumor regression in preclinical studies.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Poly(ADP-ribose) polymerase 1 (PARP-1) is a key enzyme in DNA damage response.
- PARP-1 activation by DNA breaks triggers DNA repair or cell death pathways.
- PARP-1 and PARP-2 are nuclear enzymes activated by DNA damage.
Purpose of the Study:
- To investigate the role of PARP inhibitors in modulating DNA repair and cancer therapy.
- To evaluate the efficacy of PARP inhibitors in combination with DNA-damaging agents.
Main Methods:
- Development of potent PARP inhibitors.
- Biochemical assays and genetic manipulation to study PARP-1 activity.
- Preclinical evaluation of PARP inhibitors in combination with chemotherapeutic agents.
Main Results:
- PARP inhibition increases sensitivity to DNA alkylating agents, topoisomerase I poisons, and ionizing radiation.
- Novel PARP inhibitors enhance the antitumor activity of temozolomide, topoisomerase poisons, and ionizing radiation.
- Combination of a PARP inhibitor and temozolomide led to complete tumor regression in animal models.
Conclusions:
- PARP inhibitors are valuable tools for investigating DNA repair mechanisms.
- PARP inhibitors show significant potential as modulators of DNA repair-mediated resistance to cancer therapy.
- The combination of PARP inhibitors and temozolomide is a promising therapeutic strategy currently under clinical investigation.